{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:37Z","timestamp":1792290757345,"version":"4.4.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myelofibrosis is a devastating myeloid malignancy characterized by dysregulation of the JAK-STAT pathway, resulting in splenomegaly, constitutional symptoms, anemia, thrombocytopenia, leukocytosis, and an increased likelihood of progression to acute leukemia. The only curative option is allogeneic stem cell transplantation. The numbers of transplants have been increasing every year, and although there have been improvements in survival, there remain many unanswered questions. In this review, we will evaluate patient selection and appropriate timing for transplantation. We will cover the current prognostic scoring systems, which can aid in the decision of when to move forward with transplant. We will also review the different donor options, as well as the conditioning regimens. The peritransplant management of splenomegaly will be reviewed. We will discuss management of posttransplant complications such as loss of donor chimerism or disease relapse. Finally, we will review what is known about the outlook of patients who have undergone allogeneic stem cell transplant with regards to quality of life and long-term survival.<\/jats:p>","DOI":"10.1182\/hematology.2023000453","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:30Z","timestamp":1702048470000},"page":"676-681","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Are transplant indications changing for myelofibrosis?"],"prefix":"10.1182","volume":"2023","author":[{"given":"Jeanne","family":"Palmer","sequence":"first","affiliation":[{"name":"Division of Hematology\/Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"2","key":"2023120815083572800_hem2023000453C1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2018.09.033","article-title":"Patient perspectives regarding allogeneic bone marrow transplantation in myelofibrosis","volume":"25","author":"Palmer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2023120815083572800_hem2023000453C2","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.jtct.2021.03.027","article-title":"Association of factors influencing selection of upfront hematopoietic cell transplantation versus nontransplantation therapies in myelofibrosis","volume":"27","author":"Smith","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"2023120815083572800_hem2023000453C3","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2023120815083572800_hem2023000453C4","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2023120815083572800_hem2023000453C5","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023120815083572800_hem2023000453C6","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.bbmt.2019.03.024","article-title":"Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2023120815083572800_hem2023000453C7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023120815083572800_hem2023000453C8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023120815083572800_hem2023000453C9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","article-title":"Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation","volume":"35","author":"Hern\u00e1ndez-Boluda","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2023120815083572800_hem2023000453C10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ajh.26279","article-title":"Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry","volume":"96","author":"Hern\u00e1ndez-Boluda","year":"2021","journal-title":"Am J Hematol"},{"issue":"20","key":"2023120815083572800_hem2023000453C11","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2023120815083572800_hem2023000453C12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2023120815083572800_hem2023000453C13","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2023120815083572800_hem2023000453C14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2023120815083572800_hem2023000453C15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","article-title":"Family mismatched allogeneic stem cell transplantation for myelofibrosis: report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation","volume":"25","author":"Raj","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023120815083572800_hem2023000453C16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.bbmt.2020.03.020","article-title":"Optimizing the conditioning regimen for hematopoietic cell transplant in myelofibrosis: long-term results of a prospective phase II clinical trial","volume":"26","author":"Popat","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023120815083572800_hem2023000453C17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2023120815083572800_hem2023000453C18","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3324\/haematol.2022.281958","article-title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"108","author":"Murthy","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"2023120815083572800_hem2023000453C19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023120815083572800_hem2023000453C20","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"The Lancet Haematol"},{"issue":"1","key":"2023120815083572800_hem2023000453C21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","article-title":"Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European Society for Blood and Marrow Transplantation (EBMT)","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2023120815083572800_hem2023000453C22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2021-146330","article-title":"A phase II study of ruxolitinib pre-, during- and post-hematopoietic cell transplantation for patients with primary or secondary myelofibrosis","volume":"138","author":"Hobbs","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023120815083572800_hem2023000453C23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre- hematopoietic cell transplant ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2023120815083572800_hem2023000453C24","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kr\u00f6ger","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"5","key":"2023120815083572800_hem2023000453C25","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2023120815083572800_hem2023000453C26","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023120815083572800_hem2023000453C27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"2023120815083572800_hem2023000453C28","doi-asserted-by":"crossref","first-page":"100964","DOI":"10.1016\/j.adro.2022.100964","article-title":"Pretransplant splenic irradiation in patients with myeloproliferative neoplasms","volume":"7","author":"Ponce","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"2023120815083572800_hem2023000453C29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41409-023-01913-9","article-title":"Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis","volume":"58","author":"Bales","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023120815083572800_hem2023000453C30","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2023120815083572800_hem2023000453C31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bmt.2014.323","article-title":"Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?","volume":"50","author":"Tamari","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2023120815083572800_hem2023000453C32","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3324\/haematol.2019.223503","article-title":"Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation","volume":"106","author":"Srour","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2023120815083572800_hem2023000453C33","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"2023120815083572800_hem2023000453C34","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023120815083572800_hem2023000453C35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.15407","article-title":"Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT","volume":"182","author":"McLornan","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"2023120815083572800_hem2023000453C36","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.bbmt.2019.07.001","article-title":"Assessment of quality of life following allogeneic stem cell transplant for myelofibrosis","volume":"25","author":"Palmer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2023120815083572800_hem2023000453C37","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","article-title":"Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"104","author":"Robin","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2023120815083572800_hem2023000453C38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023120815083572800_hem2023000453C39","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"2023120815083572800_hem2023000453C40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2023120815083572800_hem2023000453C41","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbmt.2014.03.017","article-title":"Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2023120815083572800_hem2023000453C42","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","article-title":"Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis","volume":"56","author":"McLornan","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023120815083572800_hem2023000453C43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ejh.13099","article-title":"Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"101","author":"Shahnaz Syed Abd Kadir","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"2023120815083572800_hem2023000453C44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2023120815083572800_hem2023000453C45","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2023120815083572800_hem2023000453C46","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41409-021-01252-7","article-title":"Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups","volume":"56","author":"Robin","year":"2021","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/676\/2175649\/676palmer.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/676\/2175649\/676palmer.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:56Z","timestamp":1702048496000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/676\/506464\/Are-transplant-indications-changing-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000453","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}